(HealthDay)—For vulnerable older patients with ovarian cancer, single-agent carboplatin is less active, with worse survival, than combination carboplatin-paclitaxel regimens, according to a study published online April ...
Apr 27, 2021
0
2
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors ...
Apr 22, 2021
0
57
For many patients with localized lung cancer (non-small-cell lung carcinoma and small cell lung carcinoma), high-dose radiation with concurrent chemotherapy is a potential cure. Yet this treatment can cause severe, acute ...
Apr 22, 2021
0
8
(HealthDay)—Chronic immune-related adverse effects after adjuvant treatment with anti-programmed cell death 1 (anti-PD-1) immunotherapies for melanoma are more common than previously thought, according to a study published ...
Apr 16, 2021
0
3
Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the Abramson ...
Apr 15, 2021
0
0
Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in ...
Apr 15, 2021
0
12
(HealthDay)—Electroacupuncture and auricular acupuncture are more effective than usual care at reducing chronic musculoskeletal pain in cancer survivors, according to a study published online March 18 in JAMA Oncology.
Apr 6, 2021
0
7
(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study ...
Apr 5, 2021
0
2
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
Mar 25, 2021
0
8
A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center ...
Feb 11, 2021
0
5
